Plasma concentrations and urinary excretion of DTZ and its metabolites were determined in 20 healthy volunteers (10 males and 10 females) after they had each been given a single oral 90 mg dose of DTZ. DTZ and six of its metabolites which included N-monodesmethyl DTZ (M A), deacetyl DTZ (M 1), deacetyl N-monodesmethyl DTZ (M 2), deacetyl O-desmethyl DTZ (M 4) and deacetyl DTZ N-oxide (M 1NO) and deacetyl N,O-didesmethyl DTZ (M 6), were determined by a sensitive and specific HPLC assay. The major metabolites measurable in the plasma of all the volunteers were M A, M 1, and M 2. The terminal half-lives (t 1/2) of M 1 and M 2 were considerably longer than those of DTZ and M A. Less than 5% of the dose was excreted as unchanged DTZ in the urine over the 24 h period. The major urinary metabolite was M A, followed by M 6, M 2, and then M 1. Except for the urinary excretion of M 4 there were no statistically significant differences in any of the pharmacokinetic parameters between the males and the females. The mean 24 h urinary recovery of M 4 was higher in the males than in the females (P< 0.05). However there were large inter-individual variations in the plasma concentrations and urinary excretion of DTZ and its metabolites with some parameters differing by more than 20-fold. In addition, O-desmethyl DTZ (M x) and N,O-didesmethyl DTZ (M B) were identified as two other major urinary metabolites.
|Original language||English (US)|
|Number of pages||8|
|Journal||European Journal of Drug Metabolism and Pharmacokinetics|
|Publication status||Published - Jun 1 1993|
- calcium antagonist
ASJC Scopus subject areas
- Pharmacology (medical)